Literature DB >> 5270914

Serum and urinary proteins, lysozyme (muramidase), and renal dysfunction in mono- and myelomonocytic leukemia.

W Pruzanski, M E Platts.   

Abstract

Serum levels, urinary excretion, and clearances of several proteins of different molecular weights were studied in 18 patients with mono- and myelomonocytic leukemia. Nine patients had normal renal function (group A) and nine had impaired renal function with azotemia (group B). The majority of patients in both groups had increased concentration of immunoglobulins, particularly IgG, IgA, and IgM; IgD level was normal. Serum transferrin and alpha(2)-macroglobulin were frequently reduced while the level of ceruloplasmin was often increased, especially in patients with azotemia. The activity of lysozyme in the serum was high in all patients, but was considerably higher in group B. Proteinuria was found in most patients but was more prominent in group B. Almost invariably albumin constituted less than 25% of the total protein excreted. Qualitative analysis of various urinary proteins by immunochemical techniques and clearance studies suggested the presence of glomerular as well as tubular dysfunction. Determination of urinary lysozyme frequently showed no direct correlation between the serum level of the enzyme and its concentration in the urine or its clearance by the kidney. In addition to glomerular filtration, impaired tubular reabsorption may account for the high level of lysozyme in the urine. It is postulated that the very high level of lysozyme in the glomerular filtrate and possibly hypergammaglobulinemia may play a role in the induction of tubular damage. Renal impairment has been correlated with histological changes in the kidneys. From a comparative study of various leukemias, it seems that the combined glomerular-tubular dysfunction is a manifestation unique to mono- and myelomonocytic leukemia.

Entities:  

Mesh:

Substances:

Year:  1970        PMID: 5270914      PMCID: PMC322653          DOI: 10.1172/JCI106387

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  35 in total

1.  [Immunoelectrophoretic method for the analysis of mixtures of antigenic substances].

Authors:  P GRABAR; C A WILLIAMS
Journal:  Biochim Biophys Acta       Date:  1955-05

2.  Clearances of some proteins by the dog kidney.

Authors:  M E MARSHALL; H F DEUTSCH
Journal:  Am J Physiol       Date:  1950-11

3.  Urinary lysozyme, ribonuclease, and low-molecular-weight protein in renal disease.

Authors:  J F Harrison; G S Lunt; P Scott; J D Blainey
Journal:  Lancet       Date:  1968-02-24       Impact factor: 79.321

4.  Clinical significance of serum and urinary muramidase activity in leukemia and other hematologic malignancies.

Authors:  P H Wiernik; A A Serpick
Journal:  Am J Med       Date:  1969-03       Impact factor: 4.965

5.  Urinary muramidase and renal disease. Correlation with renal histology and implication for the mechanism of enzymuria.

Authors:  J P Hayslett; P E Perillie; S C Finch
Journal:  N Engl J Med       Date:  1968-09-05       Impact factor: 91.245

6.  The intrarenal distribution of lysozyme (muramidase).

Authors:  M Sussman; A W Asscher; J A Jenkins
Journal:  Invest Urol       Date:  1968-09

7.  Lysozymuria and renal tubular dysfunction in monocytic and myelomonocytic leukemia.

Authors:  F M Muggia; H O Heinemann; M Farhangi; E F Osserman
Journal:  Am J Med       Date:  1969-09       Impact factor: 4.965

8.  "Myeloma protein" in a patient with monocytic leukemia.

Authors:  M D Poulik; L Berman; A S Prasad
Journal:  Blood       Date:  1969-05       Impact factor: 22.113

9.  [Automatic determination of lysozyme in the urine of different leukemias: characterization and purification of a lysozyme onlyin patients having acute myeloblastic leukemia].

Authors:  P Jollés; M Bonnafé; A Mouton; L Schwarzenberg
Journal:  Rev Fr Etud Clin Biol       Date:  1967-12

10.  The diagnostic value of lysozyme (muramidase) estimation in biological fluids.

Authors:  W Pruzanski; S G Saito
Journal:  Am J Med Sci       Date:  1969-12       Impact factor: 2.378

View more
  16 in total

1.  Disorders of the mononuclear phagocyte system. An analytical review.

Authors:  G Meuret
Journal:  Blut       Date:  1977-04

2.  A rare cause of acute kidney injury with chronic myelomonocytic leukemia.

Authors:  Marina Asano; Hanako Hase; Yuki Naruse; Kyogo Kawada; Iori Kojima; Joel Branch; Hiroshi Kitamura; Hideaki Shimizu
Journal:  CEN Case Rep       Date:  2021-01-06

3.  Hypoglycaemia in acute myelomonoblastic leukaemia: report of two cases and review of published work.

Authors:  M M Al Hilali; R V Majer; O Penney
Journal:  Br Med J (Clin Res Ed)       Date:  1984-11-24

4.  Lysozyme and hypokalaemia.

Authors:  M A Mir; S C Lodha
Journal:  Postgrad Med J       Date:  1981-03       Impact factor: 2.401

5.  Pathoanatomical features of the kidney in myelomonocytic and chronic lymphocytic leukemia.

Authors:  E W Schwarze
Journal:  Virchows Arch A Pathol Anat Histol       Date:  1975-10-30

6.  A forgotten cause of kidney injury in chronic myelomonocytic leukemia.

Authors:  Tejas V Patel; Helmut G Rennke; J Mark Sloan; Daniel J DeAngelo; David M Charytan
Journal:  Am J Kidney Dis       Date:  2009-01-29       Impact factor: 8.860

7.  [Studies of lysozyme activity in serum, urine and blood smears from patients with haematological diseases].

Authors:  L Labedzki; G Seché; P Lorbacher
Journal:  Klin Wochenschr       Date:  1977-07-15

8.  Lysozymuria and acute disorders of renal function.

Authors:  J F Harrison; R W Parker; K L De Silva
Journal:  J Clin Pathol       Date:  1973-04       Impact factor: 3.411

9.  Hyperphospholipasemia A2 in human volunteers challenged with intravenous endotoxin.

Authors:  W Pruzanski; D W Wilmore; A Suffredini; G D Martich; A G Hoffman; J L Browning; E Stefanski; B Sternby; P Vadas
Journal:  Inflammation       Date:  1992-10       Impact factor: 4.092

10.  Modulation of phagocytosis and intracellular bactericidal activity of polymorphonuclear and mononuclear cells by cationic proteins from human granulocytes: alternative pathway of phagocytic enhancement.

Authors:  W Pruzanski; N S Ranadive; S Saito
Journal:  Inflammation       Date:  1984-12       Impact factor: 4.092

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.